Home > Press > BioSante Pharmaceuticals Names Joy A. Thomas
BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced the appointment of Joy A. Thomas as vice president of corporate development. Ms. Thomas will be integral to BioSante implementing its corporate development strategies, including collaborations and licensing.
BioSante Pharmaceuticals Names Joy A. Thomas
LINCOLNSHIRE, IL | Posted on September 5th, 2007
Ms. Thomas comes to BioSante after 13 years with Baxter Healthcare Corporation where she was most recently Senior Director, Global Strategy & Business Development for its Renal Division. Earlier she was Director, Strategic Marketing and Planning for its Medication Delivery Division. Ms. Thomas holds a Bachelor of Science degree in Finance and Russian from the University of Illinois, and a Master of Business Administration in International Business and Finance from the University of Chicago.
"We are very pleased to have Joy Thomas joining us at this exciting time for BioSante," said Stephen M. Simes, BioSante's president and chief executive officer. "Joy's experience and expertise will be invaluable in assessing BioSante's strategic alternatives in view of the excellent progress we have made, especially related to FDA clarity on the development of LibiGel® in the treatment of female sexual dysfunction. We remain dedicated to our objective of maximizing stockholder value and believe Joy will be integral to this endeavor."
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine.
For more information, please click here
BioSante Pharmaceuticals, Inc.
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Artificial Forest for Solar Water-Splitting: Berkeley Lab Researchers Report First Fully Integrated Artificial Photosynthesis Nanosystem May 17th, 2013
Moth-Inspired Nanostructures Take the Color Out of Thin Films May 17th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Applied Nanotech Seeks New Chief Executive Officer: New Leader Needed for Next Phase of Growth May 10th, 2013
Cambrios Taps Sriram Peruvemba to Oversee Worldwide Marketing May 8th, 2013
TMC Names Murugesh Thimmanna National Sales Manager, India April 25th, 2013
National Space Society Adds to its Leadership Team April 24th, 2013